Born: 1956
Title: Chief Medical Officer.
Education: Doctor of Philosophy (PhD) in medicine from Copenhagen University. Master’s degree in medicine from Copenhagen University.
Employed: 2018
Background: Former Medical Director at Genmab, TopoTarget and Zealand Pharma in the development and research fields, Denmark. Medical Manager in the medical marketing field at Abbott Denmark. Advisor at Novo Nordisk and Nycomed Denmark.
Shares in Medivir: 0
Warrants in Medivir: 0
Born: 1976
Title: Chief Financial Officer
Education: MSc in Finance from Lund University, LLM from Lund University
Employed: 2018
Background: Former CFO for AstraZeneca Sweden Operations. Before that 11 years with Procter & Gamble, in global finance leadership positions in Switzerland, UK and Sweden. Founded and ran a management consultancy focusing on financial strategy and performance with clients within Life Sciences.
Shares in Medivir: 5,400 class B
Warrants in Medivir: 9,550
Born: 1961
Title: Executive Vice President Strategic Business Development
Education: Ph. D. in physical chemistry from Royal Institute of Technology and Executive MBA from Stockholm University.
Employed: 2017
Background: Former CEO of Modus Therapeutics. Prior to that Director, Corporate Development in Sobi. Responsible to build and lead the function Project & Portfolio Management in Biovitrum. Also Member of the Boards of PCI Biotech and Idogen.
Shares in Medivir: 5,000 class B
Warrants in Medivir: 4,630
Executive Vice President Strategic Regulatory Affairs and Market Access
More about Åsa HolmgrenBorn: 1965
Title: Executive Vice President Strategic Regulatory Affairs and Market Access.
Education: M. Sc. in Pharmacy, trained at Uppsala University.
Employed: 2015
Background: Former Head of Regulatory Affairs at Orexo AB. Extensive experience from a number of large pharmaceutical companies, including 12 years as Senior Global Regulatory Affairs Director at AstraZeneca, and, in particular, international, strategic duties within Regulatory Affairs. Åsa has also worked for AstraZeneca in Canada and Japan.
Shares in Medivir: 0 class B
Warrants in Medivir: 5,400
Born: 1950
Title: President and CEO
Education: PhD at Uppsala University.
Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Chairman of the Boards of Cerecor Inc., and Adhera Therapeutics, and Member of the Boards of InDex Pharmaceuticals AB, Beactica AB and Uppsala University.
Shares in Medivir: 4,000
Born: 1961
Title: Chairman of the Board. Member of the Board since 2006. Chairman of the Remuneration Committee and Member of the Audit Committee and the R&D Committee.
Education: M.Sc. in Engineering
Background: M.Sc. in Engineering with an extensive knowledge of the life sciences sector. Runs own consultancy firm operating in the fields of leadership strategy and business development. Experience of senior positions with, amongst others, GE Healthcare Life Sciences, Pharmacia, Assa Abloy, Medivir and Baxter Medical. Former President & CEO of Carmeda AB.
Other directorships: Chairman of the Board of Björn Axén. Member of the Boards of Cellavision, Pågengruppen and Probi.
Shares in Medivir: 3,724 class B shares
Born: 1950 Title: Member of the Board since 2018.
Education: PhD at Uppsala University.
Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Chairman of the Boards of Cerecor Inc., and Adhera Therapeutics, and Member of the Boards of InDex Pharmaceuticals AB, Beactica AB and Uppsala University.
Shares in Medivir: 4,000
Born: 1945
Title: Member of the Board since 2012. Chairman of the R&D Committee.
Education: Professor of Medicinal Chemistry at Uppsala University, Faculty of Pharmacy
Background: Held a number of positions as a scientific advisor at Astra Zeneca and smaller pharmaceutical companies between 1990 and 2006. Prior to this, he was the Head of the Medicinal Chemistry Department at Astra in Lund. Vice Chancellor (Rector) of Uppsala University between 2006 and 2011. He has published over 270 scientific articles, and is a co-author of a large number of granted patents. Member of the Royal Swedish Academy of Sciences, and the Royal Swedish Academy of Engineering Sciences. Awarded honorary doctorates in Sweden and other countries.
Other directorships: Member of Boards of Foundations and Universities.
Shares in Medivir: 2,500 class B shares.
Born: 1956 Title: Member of the Board since 2018.
Education: Ph.D. in Genetics from Umeå University.
Background: Extensive experience of pharmaceutical and commercial development in senior positions with both biotech and pharmaceutical companies, such as KabiGen AB, Symbicom AB, AstraZeneca, and Biovitrum AB, and as CEO of Arexis AB. Responsible for Industrifonden’s life science operations from 2008 to 2016, and currently working as a senior advisor to the fund on a consultancy basis. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies.
Other directorships: Member of the Boards of InDex Pharmaceuticals AB, Calliditas Therapeutics AB and Cinclus Pharma Holding AB. Chairman of the Boards of Ignitus AB and Sixera Pharma AB.
Shares in Medivir: 0.
Born: 1953
Title: Member of the Board since 2017. Member of the R&D Committee.
Education: M. Sc. Pharmacy. Has worked in the pharmaceutical industry since 1978.
Background: CEO of Linc AB, which invests in life sciences. Since 1990, primarily active as an investor in and a Member of the Boards of pharmaceutical development companies. Experience of developing and commercialising products.
Other directorships: Member of the Boards of Linc AB, Livland Skog AB, Calliditas Therapeutics AB, Proequo AB, Sedana Medical AB, Stille AB and Swevet AB, and a number of smaller companies.
Shares in Medivir: 958 283 class B shares (through company)
Born: 1957
Title: Member of the Board since 2015. Member of the Remuneration Committee and Chairman of the Audit Committee.
Education: B.Sc. in Economics and Business Administration from the Stockholm School of Economics
Background: Extensive experience of the financial and equity markets and of corporate governance issues. Previous employed by Neonet, Odin Förvaltning, Nordea Asset Management and SEB Asset Management, amongst others.
Other directorships: Founder and now Chairman of the Board of Nordic Investor Services AB. Member of the Boards of Concordia Maritime AB, Recipharm AB and Stendörren Fastigheter.
Shares in Medivir, including family: 5,250 class B shares
Born: 1945
Title: Member of the Board since 2017. Member of the R&D Committee.
Education: Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986.
Background: Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences. He has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers.
Other directorships: Member of the Board of Hamlet Pharma AB and several advisory groups for medical research financing.
Shares in Medivir: 4,000 class B shares.